The management of rare thoracic tumours presents unique clinical challenges and requires a multidisciplinary approach. This joint ESTRO–IASLC webinar will explore the latest evidence and emerging strategies in the treatment of mesothelioma and thymic malignancies.
This 90-minute session is organised by the ESTRO Focus Group on Lung in collaboration with IASLC and brings together international experts to share their perspectives on radiotherapy, systemic therapies, and recent trial findings, including key insights from the MARS-2 study.
Session Overview
The session will begin with a welcome from the chairs, Dr Valeria Dionisi and Dr Daniel Portik, followed by a series of concise expert presentations and an interactive Q&A.
Programme
- Introduction
Dr Valeria Dionisi and Dr Daniel Portik
- Mesothelioma: The treatment landscape after MARS-2 results
Dr Federica Grosso (on behalf of IASLC)
Duration: 12 minutes
- Is there still a role for RT in mesothelioma?
Dr Crispin Hiley
Duration: 12 minutes
- Systemic therapy in thymomas and thymic carcinoma
Dr Jordi Remon (on behalf of IASLC)
Duration: 12 minutes
- RT in thymomas and thymic carcinoma: State of the art
Dr Margaret Harris
Duration: 12 minutes
- Oligoprogression in rare thoracic cancer: Myth or reality?
Dr Andreas Rimner
Duration: 12 minutes
The presentations will be followed by an interactive Q&A session (approximately 20 minutes), offering participants the chance to engage directly with the expert panel. The session will conclude with closing remarks.
Why Attend
- Gain up-to-date insights into rare thoracic cancers
- Hear from leading international specialists
- Understand the practical implications of recent trial results
- Take part in a live discussion with the speakers
This session is particularly relevant for radiation oncologists, clinical oncologists, medical oncologists, thoracic surgeons and all professionals involved in the care of patients with rare thoracic malignancies